<DOC>
	<DOCNO>NCT00848549</DOCNO>
	<brief_summary>The purpose study ass long-term safety tolerability explore long-term efficacy zonisamide monotherapy treatment subject newly diagnose partial seizure .</brief_summary>
	<brief_title>Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>1 . Subject complete study E2090E044310 . 2 . Subject able willing give write informed consent . 3 . Female subject without childbearing potential ( two year postmenopausal , bilateral oophorectomy tubal ligation , complete hysterectomy ) eligible . Female subject childbearing potential must nonpregnant , nonlactating abide one follow medically acceptable contraceptive measure : oral contraceptive pill , contraceptive injection , implant patch , intrauterine device place least three month , vasectomise partner abstinence throughout study one month discontinuation study medication . When contraceptive pill use , contain less 50 Î¼g oestrogen . 4 . The subject able willing follow investigational study procedure , maintain seizure diary report adverse event . 1 . Subject history significant currently uncontrolled disease contraindicate use study drug interfere conduct study and/or assessment safety efficacy study drug . 2 . Subject body weight &lt; 40 kg . 3 . Subject newly occur progressive malignancy study E2090E044310 ( exclude history nonmetastasized adequately treat cutaneous squamous cell carcinoma ) . 4 . Subject develop psychiatric illness mood disorder require electroconvulsive drug therapy within previous 6 month consider uncontrolled ; history suicide attempt , alcohol drug abuse , chronic treatment benzodiazepine barbiturate . 5 . Subject currently take carbonic anhydrase inhibitor . 6 . Subject develop pancreatitis , nephrolithiasis hypercalcuria , clinically significant laboratory abnormality , stroke uncontrolled hypertension study E2090E044310 . 7 . Subject currently take monoamine oxidase inhibitor ( MAOIs ) exclude medication ( see protocol section 9.9.3 ) . 8 . Subject history allergy carbamazepine zonisamide ingredient sulphonamides . 9 . Subject develop bone marrow depression , low platelet count blood dyscrasia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Monotherapy</keyword>
</DOC>